PU.1-c-Jun interaction is crucial for PU.1 function in myeloid development

The Ets transcription factor PU.1 is essential for inducing the differentiation of monocytes, macrophages, and B cells in fetal liver and adult bone marrow. PU.1 controls hematopoietic differentiation through physical interactions with other transcription factors, such as C/EBPα and the AP-1 family member c-Jun. We found that PU.1 recruits c-Jun to promoters without the AP-1 binding sites. To address the functional importance of this interaction, we generated PU.1 point mutants that do not bind c-Jun while maintaining normal DNA binding affinity. These mutants lost the ability to transactivate a target reporter that requires a physical PU.1-c-Jun interaction, and did not induce monocyte/macrophage differentiation of PU.1-deficient cells. Knock-in mice carrying these point mutations displayed an almost complete block in hematopoiesis and perinatal lethality. While the PU.1 mutants were expressed in hematopoietic stem and early progenitor cells, myeloid differentiation was severely blocked, leading to an almost complete loss of mature hematopoietic cells. Differentiation into mature macrophages could be restored by expressing PU.1 mutant fused to c-Jun, demonstrating that a physical PU.1-c-Jun interaction is crucial for the transactivation of PU.1 target genes required for myeloid commitment and normal PU.1 function in vivo during macrophage differentiation.
The differentiation of hematopoietic stem cells (HSC) to various mature blood cell lineages is a process tightly regulated by the concerted action of a network of transcription factors, integrating signaling cascades triggered by extrinsic stimuli. PU.1 has been identified as an essential transcriptional regulator of hematopoiesis, required at multiple stages of myeloid and lymphoid differentiation. PU.1 can be detected in HSC, at higher levels in the common myeloid progenitors (CMP), and at high expression levels in granulocyte-macrophage progenitors (GMP) and mature myelomonocytic cells. Within the lymphoid lineage, it is expressed in common lymphoid progenitors (CLP) and in pro-B and mature B lymphocytes. PU.1 regulates the expression of almost all myeloid genes, including the cytokine receptors M-CSF-R, GM-CSF-R, and G-CSF-R.

Loss of PU.1 expression leads to perinatal death with severe defects in the lymphoid and the myeloid lineages with a lack of monocytes/macrophages, B and T cells at birth. Additionally, studies using conditional PU.1 knockout mice suggest that PU.1 plays an important role in the maintenance of the adult HSC pool and is required for the generation of CMP and CLP. While the loss of PU.1 in CMP prevents their maturation, it does not affect the proliferation of myeloblastic cells in culture. However, PU.1 restricts excessive divisions of both normal hematopoietic stem cells (HSC) and leukemia “stem cells.” At the same time, reduction of PU.1 levels below 20% of wild-type levels, as well as Mx1-Cre-mediated conditional deletion of PU.1 in the hematopoietic lineages, have been shown to cause leukemias in adult mice.

Aside from binding to cognate DNA sequences in the promoters and enhancers of its target genes, PU.1 also binds to multiple other transcription factors. Known partners include GATA-1, GATA-2, GATA-3, RUNX1 (AML1), C/EBPβ, C/EBPδ, Ski, Evi-1, Rh, Bcl6, IRF4, and ICSBP/IRF8. These interactions can modulate the transcriptional activity of PU.1. One example of an antagonistic interaction is the one described for PU.1 and GATA-1, which has been proposed as a general model for the initiation and resolution of mixed lineage states occurring during the differentiation of multipotent progenitors. It further emphasizes that direct physical interactions between transcription factors are critical events for hematopoietic cell differentiation.

An example of a co-operative activation of target genes has been described for PU.1 and c-Jun, a member of the AP-1 transcription factor family, which includes JunB, JunD, and the Fos family, all of which are expressed in hematopoietic cells. The AP-1 family has diverse effects, including the promotion of proliferation, differentiation, and apoptosis. In the course of hematopoietic differentiation, c-Jun is upregulated during monocytic differentiation of myeloid cell lines and expressing a dominant negative c-Jun blocks monocytic differentiation. When acting as part of the AP-1 complex, c-Jun is a bona fide transcription factor and interacts with a specific DNA-binding site, either as a homodimer or as a heterodimer with other AP-1 family members. However, c-Jun can play a different role when it interacts with PU.1. We previously reported that c-Jun directly binds and coactivates PU.1 on the M-CSF-R and IL-1β promoters, which lack AP-1 binding sites, demonstrating that c-Jun acts in these cases as a coactivator of PU.1 function, rather than as a classic transcription factor binding DNA. The PU.1 region contacting c-Jun has been mapped to the Ets domain, whose three-dimensional structure has been extensively characterized. This winged helix-turn-helix motif is conserved among Ets family members and serves both as a DNA-binding domain and a protein interaction domain with c-Jun.

To address the importance of the interaction of PU.1 and c-Jun for hematopoietic cell differentiation, we generated and identified PU.1 mutants that do not physically interact with c-Jun but still retain intact DNA-binding capabilities. We isolated three mutants that satisfied these two criteria. In contrast to wild-type PU.1, these mutants exhibited impaired transcriptional activation ability and were unable to induce monocytic differentiation of a PU.1-deficient cell line. Moreover, mice carrying these mutations displayed an early block in myeloid differentiation and died perinatally. These results suggest that the induction of myeloid cell differentiation by PU.1 is dependent on the interaction with the PU.1 coactivator c-Jun. These findings are in line with the proposed mechanism of AML1-ETO-mediated myeloid leukemias in which the AML1-ETO fusion disrupts PU.1-c-Jun interaction and thereby leads to a differentiation block and malignant transformation.

Results
Generation of PU.1 mutants defective in c-Jun interaction. To address the functional importance of the PU.1-c-Jun interaction for target gene activation, we performed a mutagenesis screen to identify PU.1 point mutations that specifically abolish binding to c-Jun while maintaining PU.1-DNA-binding. Briefly, we generated a library of PU.1 mutants by random PCR mutagenesis and tested these mutants in the yeast split-hybrid system (Supplementary Methods) for c-Jun interaction as previously described. More information on the screen is shown in Supplementary Fig. S1. Mutants defective in c-Jun binding were analyzed by electrophoretic mobility shift assay (EMSA) for their DNA-binding capability. We identified three mutations that stringently met these two criteria (Fig. 1a). The Y252N mutation identified in this screen is located in the β4 beta-sheet of the Ets domain. This is in accordance with previous studies that mapped PU.1-c-Jun interactions to the β3/β4 region, comprising amino acids 243–254 of PU.1. In addition, we found two adjacent c-Jun binding-deficient mutations (Q202L and F203Y) located in the β2 region of PU.1. Importantly, the crystal structure of the PU.1-DNA-binding domain bound to DNA demonstrates that the β2 and β3/β4 regions are directly adjacent and that the mutated amino acids are not located on the DNA-binding surface of the Ets domain.

To determine more precisely their DNA-binding affinities, we performed a dissociation gel shift assay, in which each PU.1 protein was first incubated with a labeled PU.1 binding site oligonucleotide, and subsequently competed with an excess of unlabeled competitor oligonucleotide to measure the dissociation of the labeled complex over time. As shown in Fig. 1b, the Q202L and Y252N mutants bound to DNA with an affinity comparable to that of wild-type, while the F203Y mutant showed slightly lower affinity. As a control, none of the PU.1 proteins bound a similar DNA probe with a disrupted PU.1 site.

To ascertain that the isolated PU.1 mutants lost the ability to interact with full-length c-Jun in mammalian cells, we coexpressed the PU.1 mutants and c-Jun and performed co-immunoprecipitation experiments (Supplementary Methods). As shown in Fig. 1c, all three PU.1 mutants described here lost the c-Jun interaction in 293T cells. Therefore, we have identified PU.1 mutations that meet the criteria of conserved DNA-binding and disrupted c-Jun interaction.

PU.1 mutants have an impaired in vitro transactivation and differentiation potential. To assess the impact of the impaired PU.1-c-Jun interaction on PU.1 transcriptional activity, we performed luciferase assays in either CV-1 cells, which contain endogenous c-Jun, or F9 cells that lack it. Cells were co-
transfected with the previously described PU.1-responsive human M-CSFR promoter reporter and PU.1 wild-type or mutant (Q202L, F203Y, and Y252N) expression constructs. Additionally, c-Jun was co-expressed to test its coactivation potential. Similar to what we have shown before, wild-type PU.1 alone activated the M-CSFR promoter (3-fold in CV-1 cells, 7-fold in F9 cells). Co-transfection of PU.1 and c-Jun resulted in a synergistic activation (15-fold in CV-1 cells, 25-fold in F9 cells) (Fig. 2a). In the F9 cells, The PU.1 mutants were able to activate reporter transcription only 2-fold (compared to 7-fold for wild-type) in the absence of c-Jun, and only 3.5-fold for Y252N and 5-fold for Q202L and F203Y in the presence of c-Jun protein (compared to 25-fold for...
wild-type PU.1). Hence, the PU.1 mutants failed to synergize with c-Jun to activate transcription of the M-CSFR promoter, suggesting that the PU.1-c-Jun interaction is required for robust transcriptional activation of this target gene. Similar results were obtained with a minimal promoter containing four PU.1 binding sites, demonstrating that the synergistic activation by PU.1 and c-Jun is dependent solely upon PU.1 sites and, furthermore, is not restricted to the M-CSFR promoter. To exclude the possibility that the mutations affect the predominantly nuclear localization of the PU.1 protein, we studied the subcellular localization and observed a similar localization pattern of the wild-type and mutant proteins (Supplementary Fig. S2). Taken together, these results suggest that a direct interaction between PU.1 and c-Jun is necessary for robust activation of certain PU.1 target genes.

Given the evidence of a crucial function of c-Jun in monocytic differentiation, we tested the implications of the disrupted PU.1-c-Jun interaction on monocytic differentiation. For this, we reintroduced either wild-type or mutated PU.1 into the PU.1-deficient, immature myeloid cell line 503. Wild-type PU.1 and mutants (Q202L, F203Y, and Y252N) were subcloned into the retroviral vector MIGRI, transduced into 503 cells, and sorted for EGFP expression. Upon 10 days of culture with M-CSF, wild-type PU.1/503 cells clearly differentiated into monocytes (featuring large, light-blue cytoplasm and cleaved nucleus), as well as into macrophages (adherent to the dish and performing phagocytosis) and mature granulocytes. In contrast, 503 cells transduced with PU.1 mutants were not adherent and had immature myeloid blast features with typical dense blue, round-shaped nuclei and small cytoplasm, similar to the mock-transduced 503 cells (Fig. 2b).

The failure of mutant PU.1 to induce monocytic differentiation was further assessed by monitoring cell surface expression of F4/80, a marker of mature monocytes and macrophages. Following sorting, surface markers for monocytic differentiation were analyzed by flow cytometry on day 7. While the addition of wild-type PU.1 promoted monocytic differentiation, as marked by F4/80 expression, none of the three mutants was able to increase the number of cells expressing F4/80 compared to mock-transduced cells. Similar amounts of PU.1 protein were detected in sorted EGFP+ cells by Western blot analysis, demonstrating that the inability to differentiate was not caused by lower PU.1 protein concentrations (Fig. 2c). These results indicate that the PU.1 mutants have an impaired in vitro transactivation and lack the potential to induce myeloid differentiation.

**PU.1 mutant mice display an early lymphoid-myeloid differentiation block.** The obvious impact of the point mutations on monocytic differentiation in cell culture prompted us to study the in vivo importance of PU.1-c-Jun interactions. We generated mice with a targeted mutation of the PU.1 gene, introducing the identified single-point mutations (Fig. 3a, b). Three independent knock-in mouse lines were established, carrying the Q202L, F203Y, or Y252N mutation, respectively. In the following, we will focus on the Q202L mutation, which showed the highest DNA-binding ability in vitro (Fig. 1b), but the results obtained with the F203Y mutation closely match those reported here for the Q202L mutation.

When bred to homozygosity, the Q202L mutation knock-in (KI) mice were either born dead or died during the first day after birth. Analysis of litters at embryonic day 14.5–16.5 revealed that homozygous pups developed with normal Mendelian ratios. As the knock-in mice did not survive to the adult stage, we evaluated the progenitor populations in the fetal liver. To examine the role of the PU.1-c-Jun interaction on HSC self-renewal, we employed serial replating of total fetal liver cells from the WT or Q202L PU.1 mutant. Strikingly, abolishing the PU.1-c-Jun interaction impaired the ability of fetal liver cells to proliferate (Fig. 3c).

Further characterization of the fetal liver of these embryos revealed the complete absence of mature granulocytic and monocytic cells. In addition, there was a strong reduction in the total numbers B and T lymphocytes (Fig. 3d).

Next, we characterized the fetal liver progenitor compartment. The analysis of the fetal liver progenitor compartment showed a substantial reduction of common CMP and GMP, but not of myeloid-erythroid progenitors (MEP), in which PU.1 is not essential (Fig. 3e). To characterize the HSC compartment by staining for CD48 and CD150, abolishing the PU.1-c-Jun interaction caused a statistically significant decrease in the number of the multipotent progenitor (MPP) population with a concomitant accumulation of both long-term HSCs (LT-HSC) and short-term HSCs (ST-HSCs) (Fig. 3f). These results further support a differentiation block downstream of the HSC stage in the absence of a functional PU.1-c-Jun interaction.

Protein expression analysis using whole cell extracts of the unfractionated fetal liver did not show any detectable PU.1 expression in the mutants. To test whether this was caused by the lack of the cells normally expressing PU.1 (B cells, granulocytes, monocytes), or by a failure of the targeted construct to generate mRNA and protein, sorted hematopoietic stem and progenitor cells were analyzed for PU.1 transcription by quantitative real-time PCR (qPCR) (Supplementary Fig. S3). The c-kit+Sca-1−lin– progenitor cells that express high levels of CD16/CD32 (FcγRII/III, similar to GMP), but low levels of CD34, have high levels of PU.1 transcript, similar to wild-type GMP. We sorted this population and performed western blot analysis of the PU.1 protein using comparable numbers of wild-type GMP and this aberrant population found in the mutant mice. Mutant PU.1 protein was indeed expressed (Supplementary Fig. S3), suggesting that the loss of the hematopoietic cells downstream of these cells is caused by a functionally defective PU.1 protein rather than by reduced PU.1 levels. This is in contrast to other PU.1 models, such as the previously characterized PU.1 ΔE6 knock-out model or the PU.1 conditional knock-out model.

To ensure that the point mutation specifically abolishes the PU.1-c-Jun interaction, we tested the capability of PU.1 to...
interact with other transcription factors. As shown in Supplementary Fig. S4, the interactions of mutant PU.1 with C/EBPα, as well as with GATA-2 remain intact, albeit slightly decreased. These results strongly suggest that physical PU.1-c-Jun interaction is crucial for early lympho-myeloid differentiation in vivo.

Expression of a mutant PU.1 fused to c-Jun partially rescues the differentiation block. To demonstrate that the reduced transcriptional activity of PU.1 mutants was caused specifically by the failure to interact with and recruit c-Jun to target promoters, we performed rescue experiments using mutant PU.1 fused to c-Jun via a flexible poly-linker (Fig. 4a). Newborn liver cells were
isolated and transduced with retroviruses carrying different expression constructs, as well as enhanced green fluorescent protein (EGFP) driven by an internal ribosomal entry sequence (IRES). Transduced EGFP+ cells were subsequently isolated by flow cytometry and cultured for 14 days in a semi-solid M3434 medium containing SCF, IL-3, IL-6, and EPO. Expression of mutant PU.1 alone was not sufficient to overcome the differentiation block caused by the absence of wild-type PU.1 at an early monocyte/macrophage stage, observed in KI fetal liver. The cells kept an immature morphology similar to the mock-transduced cells. However, the introduction of either wild-type PU.1, or mutant PU.1 fused to c-Jun triggered differentiation into mature macrophages with large, highly vacuolated cytoplasm and small eccentric nucleus expressing high levels of the late monocyte marker F4/80 at day 14 cultured in differentiation medium (Fig. 2a, 2c, lower left panel). Three independent experiments were performed with representative images shown. c Cell surface expression of the late macrophage marker F4/80 correlates with morphological signs of differentiation. 503 cells transduced with wild-type (PU.1-wt) or mutant PU.1(Q202L, Y252N and F203Y), or with empty retroviral expression vector (Vector). Infected (EGFP+) cells were sorted, cultured for 10 days in differentiation medium and analyzed by flow cytometry for expression of F4/80 and EGFP expression. Protein extracts of the sorted cells were used for western blots analysis to assess PU.1 expression levels. (Fig. 2c, lower left panel). Three independent experiments were performed with representative images shown. Source data for the blot can be found in Supplemental Data 1.

Loss of interaction of PU.1 with c-Jun affects a subset of PU.1 target genes. To identify PU.1 target genes that help explain the severe differentiation block observed in the KI mice, and to assess the fraction of PU.1 target genes that are affected by the mutation, we sorted ST-HSC (CD150−CD48−LSK) from the fetal liver of KI and wild-type embryos (WT), a differentiation stage equally present in wild-type and mutant mice, as well as wild-type GMP (lin− c-kit+ Sca-1+ CD16/32hi CD34+), and the GMP-like population (lin− c-kit+ Sca-1− CD16/32hi CD34inh) appearing in mutant mice. We purified the RNA, performed cDNA synthesis, linear amplification, and microarray analysis to compare global gene expression changes between the samples. Significant differences in gene expression patterns between wild-type and mutant samples occurred already at the ST-HSC stage. Using the SAM algorithm to assess significant changes between the populations, we identified 25 genes that were upregulated and 61 genes that were downregulated in the mutant compared to wild-type ST-HSC, showing that mutation of PU.1 already affects these very immature hematopoietic precursor cells (Fig. 5a, b). RT-qPCR was also utilized to further validate the expression differences observed (Supplementary Fig. S5, Supplementary Table 1). To assess the importance of the PU.1-c-Jun interactions, we focused on the gene expression of direct PU.1 target genes that have been experimentally determined previously58. We observed downregulation of a number of known targets in mutant ST-HSC and GMP-like cells, including, as expected, the gene encoding the M-CSF-R, but also other genes involved in macrophage recruitment and differentiation, such as the cysteine protease Cathepsin S (Ctss), and Tyro3b (DAP-12), an adapter protein coupling M-CSF-R signaling to stabilization and nuclear translocation of β-catenin57. Similarly, the IL-7 receptor alpha chain (Il7r), important for B-lineage differentiation, was significantly downregulated already in the ST-HSC population. In contrast, other direct PU.1 target genes, such as Blnk, the LPS co-receptor CD14, as well as Ly96, an adapter of TLR4 involved in LPS responsiveness, were unaffected by the mutation (Tables 1,2). Of note, neither PU.1, nor c-Jun mRNA expression were significantly altered in the sorted cell fractions from the PU.1 mutant mice (Table 3).

The AP-1 motif is highly enriched in promoters of unaffected PU.1 target genes. PU.1 binding sites have been mapped by chromatin immunoprecipitation-coupled deep sequencing (ChIP-seq) in the PU.1-inducible myeloid progenitor cell line Puer58, as well as in peritoneal macrophages and in B cells56,57. To correlate the gene expression observed in our PU.1 mutant cells with putative PU.1 binding, we analyzed the published data from Heinz and colleagues58, obtained with puer cells. First, we divided all expressed genes into three groups based on their differential expression within the PU.1 mutant populations: unaffected, downregulated or upregulated in comparison with wild-type cells. We then considered the PU.1 binding sites localized within each gene or its ±50 kb flanking region as potential PU.1 target sites. We subsequently retrieved the corresponding DNA sequences and performed a Position Weight Matrix (PWM) search using PscAn59 on current public transcription factor databases: Jaspar60 and Uniprobe61. The PWM search allowed us to identify transcription factor binding sites associated with PU.1 within the three groups. Jaspar uses the consensus sequence TgANNTCA as AP-1 matrix (Fig. 5c, left panel), while Uniprobe uses two matrices describing the binding site of the AP-1 transcription factors: The first matrix corresponds to the canonical AP-1 matrix, while the second has an additional nonconserved residue in the center of the motif (TgANNTCA) (Fig. 5c, middle and right panel) and is the consensus site for Jundm2, another member of the Jun family. According to PscAn, when searching the promoter region (~950 ± 50 bp) of the unaffected genes noted in Table 3 against the TRANSFAC database, the top transcription factor candidate was AP-1 with p = 0.0012. The 2nd and 3rd candidates are STAT3 (p = 0.0025) and BACH2 (p = 0.0041). It is therefore evident that the best matching TF motif identified in the unaffected genes is AP-1. We also noted the absence of Pu.1 partner TF’s such as CEBPA (p = 0.26) and GATA-2 (p = 0.32), GATA-1 (p = 0.29), MYB (p = 0.42), and AML1 (p = 0.51). As shown in Fig. 5c, we found a noticeable enrichment of the AP-1-binding motif in the regions immunoprecipitated by PU.1 in genes that were not affected by the PU.1 mutation. Moreover, the Jundm2 primary matrix, which allows a gap of 2 nucleotides between both halves of the core motif, is significantly over-represented in the unchanged group compared to the
downregulated group. This finding could explain how a subset of bona fide PU.1 target genes is still activated by the PU.1 mutant that cannot directly recruit c-Jun to form a transcriptional coactivator complex. Therefore, the direct interaction of PU.1 and c-Jun appears to be crucial in regulatory regions without AP-1 sites adjacent to PU.1, while the binding of both factors in close proximity to each other might alleviate the requirement of a robust direct interaction to form a ternary complex.

**Discussion**

PU.1 is a master regulator of myelopoiesis and lymphopoiesis due to its crucial role in directing the generation of monocytes and
lymphocytes. Furthermore, PU.1 cooperates with several transcription factors to orchestrate entire transcriptional networks that establish cellular identity or drive the differentiation of multipotent progenitor cells into distinct lineages. We have previously identified c-Jun to be a direct interaction partner of PU.1 that plays a role in monocytic differentiation. PU.1 interacts via the Ets domain with the basic domain of c-Jun in vitro, and the recruitment of c-Jun by PU.1 enhances the activity of the M-CSF-R promoter, which lacks an AP-1-DNA-binding site. We investigated the importance of this interaction for PU.1 function using PU.1 mutants which fail to interact with c-Jun but still retained DNA-binding ability. These mutations are located in the β2 and β3/β4 regions of the Ets domain, on a molecular surface facing away from the DNA, suggesting that this surface area participates directly in PU.1-c-Jun protein–protein interactions. We did not identify any mutations in the PEST domain, suggesting that this domain, which mediates interactions with IRF factors, does not play a role in the PU.1-c-Jun interaction. Our findings are consistent with previous reports of interactions between the PU.1 Ets domain and c-Jun. Furthermore, the PU.1 mutants maintained intact binding to C/EBPα and GATA-2, confirming the specificity of the mutation sites.

We previously showed in a PU.1 knockdown model that c-Jun overexpression can help overcome the myelomonocytic differentiation block caused by substantially reduced PU.1 expression in vitro. While that model demonstrated the importance of both PU.1 and c-Jun for monocytic differentiation, it neither dissected the requirement of their interaction on the protein level nor did it address terminal macrophage differentiation. Here we provide evidence that direct interaction of PU.1 with c-Jun is absolutely required to allow PU.1-mediated macrophage differentiation.

In the present manuscript, the importance of the PU.1-c-Jun interaction was further demonstrated in vivo by the generation of a PU.1 mutant knock-in mouse model. We observed an early block of hematopoietic differentiation with an accumulation of cells at a GMP-like stage with consecutive loss of the more mature myeloid populations, which is absent in PU.1-deficient mice. This suggests that the mutant PU.1 maintains residual function and might affect a subset of PU.1 target genes, presumably those genes that require recruitment of c-Jun for activation. In contrast to PU.1 knockdown and knock-out models, the observed effect is not caused by reduced PU.1 levels, as we can detect both mRNA and protein in amounts that surpass 50% of wild-type levels in the stem and progenitor cell populations (Supplementary Fig. S3). PU.1<sup>Q202L</sup> mice, however, have a normal phenotype, in line with the observation that only mice expressing 20% or less of PU.1 wild-type levels show a phenotype. To show that specifically the interaction of PU.1 with c-Jun is required for myeloid differentiation, we generated a rescue construct consisting of c-Jun tethered to mutant PU.1 protein and expressed it in mutant LSK cells. The in vitro data presented here show that PU.1-c-Jun interactions are essential for the differentiation of progenitors into mature monocytes and macrophages and that a fusion construct of c-Jun tethered to mutant PU.1 was able to rescue this process, while overexpression of c-Jun in the background of the PU.1 mutant did not have a beneficial effect on monocytic differentiation.

While the B and T lymphoid, as well as the myeloid lineages, were virtually absent in the fetal liver of mutant mice, MEMP and erythroid cells were essentially normal, suggesting that PU.1-c-Jun interactions are not required in this lineage. Our mouse model suggests, similar to the model of Jacobsen and colleagues, that MEMP are not necessarily derived from LMMP, but can branch off directly from an earlier progenitor or HSCs. Our PU.1 mutant knock-in mouse model could be a useful tool to study this hypothesis.

To gain further insight into the pathways affected by the mutation, we sorted ST-HSC and the GMP-like population from mutant fetal liver and compared their gene expression profile with wild-type ST-HSC and GMP populations. We observed that a number of genes were deregulated in ST-HSC, emphasizing the fact that functional PU.1 is required for normal gene expression already at this early differentiation stage. Interestingly, closer inspection of known direct PU.1 target genes, previously characterized in immature myeloid cells, revealed a subset that was unaffected by the PU.1 point mutation, including Blk, Ly96, and CD14. In addition, mRNA expression of PU.1 itself, but also of c-Jun and JunB, was unchanged in both ST-HSC and GMP-like cell populations.

Other groups have carried out global studies of PU.1 binding and target gene expression in both myeloid and lymphoid cells. These studies identified a large number of PU.1 binding regions within the regulatory regions of genes that were activated upon induction of PU.1 expression, thereby being bona fide direct...
PU.1 target genes. Using these regions as references, we queried the list of genes expressed in the ST-HSC of the mutant mice for common binding motifs. We identified an enrichment of AP-1 sites in the regulatory regions detected by ChIP-seq in genes that were not affected by the PU.1 mutation. Additionally, a motif associated with the related AP-1 transcription factor Jdm2, consisting of a very similar binding matrix, was highly enriched in the genes that were unaffected by the PU.1 mutation compared with genes that were downregulated. These findings suggest that, in this case, direct DNA binding of c-Jun adjacent to PU.1 could allow the assembly of PU.1-c-Jun complexes even when protein–protein interactions are disrupted. In scenarios in which
c-Jun binding cannot occur adjacent to PU.1, such as in the M-CSFR promoter, direct protein–protein interactions might be absolutely required for PU.1–c-Jun coactivation to occur, as our experimental data suggests. The occurrence of non-consensus AP-1 motifs that cannot bind AP-1 complexes in the absence of experimental data suggests. The occurrence of non-consensus AP-1 motifs that cannot bind AP-1 complexes in the absence of our experimental data suggests. The occurrence of non-consensus AP-1 motifs that cannot bind AP-1 complexes in the absence of our experimental data suggests.

The relevance of the PU.1-c-Jun interaction is further corroborated by the fact that abolishing the PU.1-c-Jun interaction enhanced the self-renewal capacity of fetal liver cells in serial replating experiments (Fig. 3C). This sustained self-renewal of fetal liver cells suggests that the PU.1-c-Jun interaction is important for promoting myeloid differentiation and that the absence of the PU.1-c-Jun interaction could potentially contribute to myeloid leukemia. Such enhanced self-renewal is observed in cells transfected with the oncogenic fusions HRX-ENL67, AML1-ETO68, and MOZ-TIF269.

Similar to the observed combinations of PU.1 and C/EBPβ in myeloid cells, and PU.1 and E2A in B cells88, the PU.1-c-Jun combination studied here might act as a beacon for the assembly of cell-type and differentiation-specific promoter complexes. It would be of interest to perform similar ChIP-seq experiments using PU.1 and c-Jun in wild-type and mutant backgrounds to analyze target gene-specific sequence motifs to further dissect this critical interaction.

Materials and methods

Generation of PU.1 mutants which bind DNA but do not interact with c-Jun. PU.1 point mutations in the Ets domain were generated by random PCR mutagenesis89. Mutants were subsequently screened by a yeast split-hybrid assay as previously described88. Detailed information about the screen can be found in the supplement. Mutants defective in c-Jun binding were further analyzed by electrophoretic mobility shift assay (EMSA) for their DNA-binding capability.

Electrophoretic mobility shift assays (EMSA).

In vitro recombinant human PU.1 protein was produced by Sp6 priming using the TNT kit (Promega) and 35S-labeled methionine (PerkinElmer Life Sciences). Two microliters of total protein from the TNT reaction was loaded on a 6% SDS-PAGE gel to confirm efficient translation and equivalent protein production of human PU.1 wild-type and mutant proteins. Oligonucleotides derived from the CD11b promoter containing a defined PU.1 binding site were annealed to form a double-stranded probe, radiolabeled with 32P-Y-ATP (PerkinElmer Life Sciences) by T4 polynucleotide kinase (New England Biolabs), and purified through a Sephadex G-25 column (Roche Applied Science). EMSA was performed using previously published conditions70.

Co-immunoprecipitations and western blotting analysis. PU.1 wild-type and mutants were cloned into the mammalian expression vector pcDNA3 and labeled with an in-frame N-terminal Flag tag. Similarly, human c-Jun cDNA was cloned with an N-terminal Myc tag into pcDNA3. These constructs were transiently co-transfected into 293 T cells using Lipofectamine LTX (Invitrogen). Forty-eight hours after transfection, cells were harvested, washed in PBS, and lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% Triton X-100 and protease inhibitor cocktail (Roche) by incubating on ice for 20 minutes and passed three times through a 28-gauge syringe. After centrifugation at 16,000 × g for 10 minutes at 4 °C, the lysate was collected. Then, 40 μl of anti-FLAG M2-agarose (Sigma) was used for supershift. The remaining 40 μl of lysate was assayed with luciferase reagent (Promega) and treated with an equal amount of PU.1 wild-type promoter and protein DNA oligonucleotides from the human CD11b promoter41. We confirmed by western blot that an equal amount of PU.1 wild-type and mutant proteins were in vitro-translated using 1 μg of DNA in the pcDNA3 vector. These in vitro-translated proteins were then incubated with radiolabeled oligonucleotides for 20 min on ice. After retrieving the first sample (t = 0), a 25-fold excess of unlabelled oligonucleotides was added to the reaction. Aliquots taken at the indicated time points after the addition of competitor were loaded onto 6% polyacrylamide gels, run in 0.5% TBE buffer, and analyzed by exposing the dried gels on BioMax MS film (Kodak).

Transient transfection and luciferase reporter assays. CV-1 and F9 cells were cultured in DMEM + 10% FBS. For transcriptional activation studies, full-length wild-type and mutant PU.1 in pcDNA3, pSV1-SPORT-c-Jun, and the pXP2-M-CSF receptor promoter fused upstream of a luciferase reporter41, or pXP2 alone, were transiently transfected into CV-1 or F9 cells with Lipofectamine and PlusReagent (Invitrogen). The remaining 40 μl of lysate was loaded onto a 10% SDS-PAGE gel and run in 0.5% TBE buffer, and proteins were detected by X-ray film exposure. The films were visualized with a PCX-101 (KONICA MINOLTA). Western blots were probed with antibodies against c-Jun (Santa Cruz, sc-649, H-79, JUN), PU.1(Santa Cruz, sc-352, T-21, Spi-1), FL (Sigma, F3165, M2), or c-Myc (Novus, NBP1-97617, PL14, MYC). WR quantification was performed using ImageJ.

Retroviral transduction of mouse cells. The PU.1-deficient, immature myeloid cell line 5034 were cultured in IMDM + 10% FBS, 5% WEHI conditioned medium, and 3% BHE conditioned medium as a source of IL-3 and SCF, respectively. For retroviral transduction, wild-type and mutant PU.1 constructs were subcloned into the MIGRI vector (kindly provided by Harinder Singh) in the EcoRI site56. Retrovirus was generated by transient transfection with 5 μg of MIGRI-PU.1, 1 μg of PHCMV-A-MLVenv, and 1 μg of pGag (kindly provided by Carol Stocking, University of Minnesota, St Paul, Minnesota, USA) using the DEAE-dextran method as described previously56.
Heinrich-Pette-Institute, Germany) into 5 × 10^6 Phoenix amphotropic packaging cells (Orbigen) using Lipofectamine and Plus Reagent according to the manufacturer’s instruction (Invitrogen). After 48 hours, the supernatant was harvested and passed through a 0.45 μm filter (MILLEX-HA, Millipore). For retroviral transduction, 1 × 10^3 cells were incubated with 1 ml viral supernatant and 10 μg/ml of Hexadimethrine bromide (10868-9, Aldrich Chem. Co) in fibronectin-pretreated wells (10 mg/ml of Fibronectin, F-0895 SIGMA, 1146 Becton Dickinson). After spinoculation at 800 × g for 120 min, 1 ml of fresh medium was added to the cells. After 24 h, a second spinoculation was carried out. Forty-eight hours after the first transduction, GFP expression in 503 cells was examined by flow cytometry. PU.1 expression was determined by Western blotting with anti-PU.1 antibody at 1:1000 dilution (Santa Cruz sc-352). The membrane was stripped with 100 mM, washed with PBS, and incubated with appropriate antibodies in PBS containing 5% calf serum for 30 min on ice in a total volume of 20 μl. The cell pellet was washed three
times with PBS and suspended in PBS containing 2% calf serum. Analyses were performed with FACS can and CellQuest software (Becton Dickinson) or LSRII (Becton Dickinson) and FlowJo software (Tree Star). Fluorescence-conjugated antibodies used include anti-murine CD11b (M1/70), Gr-1 (RB6-8C5), F4/80 (Becton Dickinson) and FlowJo software (Tree Star). Fluorescence-conjugated antibodies used include anti-murine CD11b (M1/70), Gr-1 (RB6-8C5), F4/80 (Becton Dickinson) and FlowJo software (Tree Star).

**Table 1 Selected genes dysregulated in PU.1 mutant ST-HSC.**

| Gene symbol | Gene title | Probe ID   | Fold change (log2) |
|-------------|------------|------------|--------------------|
| H2-Aa       | Histocompatibility 2, class II antigen A, alpha | 1435290_x_at | -8.56              |
| CD74        | CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) | 1425519_a_at | -7.03              |
| H2-Eb1      | Histocompatibility 2, class II antigen E beta | 1417025_at | -6.30              |
| H2-Ab1      | Histocompatibility 2, class II antigen A, beta-1 | 1450648_s_at | -6.28              |
| H2-DMb2     | Histocompatibility 2, class II, locus Mb2 | 1443686_at | -4.71              |
| March1      | Membrane-associated ring finger (C3HC4) 1 | 1440209_at | -4.34              |
| H2-DMa      | Histocompatibility 2, class II, locus DMa | 1422527_at | -3.42              |
| Fgcr        | Fc receptor, IgG, alpha chain transporter | 1416978_at | -3.67              |
| Ctsk        | Cathepsin 5 | 1448591_at | -7.88              |
| Mpeg1       | Macrophage expressed gene 1 | 1427076_at | -7.73              |
| Csf1r       | Colony stimulating factor 1 receptor | 1419872_at | -6.84              |
| Irf8        | Interferon regulatory factor 8 | 1416714_at | -6.20              |
| Tcfc        | Transcription factor EC | 1419537_at | -3.81              |
| Lyz         | Lysozyme | 1436996_x_at | -3.25              |
| Lysz        | Lysozyme | 1423547_at | -2.92              |
| B-cell genes | |           |                   |
| Il17r       | Interleukin 7 receptor | 1448575_at | -4.72              |
| Igk-6       | Immunoglobulin heavy chain 6 (heavy chain of IgM) | 1427351_s_at | -3.16              |
| Gcet2       | Germinal center expressed transcript 2 | 1420544_at | -2.73              |
| Ptprc       | Protein tyrosine phosphatase, receptor type C | 1422124_a_at | -2.62              |
| Tnfsf3B     | Tumor necrosis factor receptor superfamily, member 1b | 1423162_at | -2.57              |
| T-cell genes | |           |                   |
| Cd27        | CD antigen 27 | 1452389_at | -3.46              |
| Il13r1      | Interleukin 13 receptor, alpha 1 | 1427165_at | -3.94              |

**OP9 co-culture assay.** Sort LSK from both wild-type and knock-in E14.5–16.5 fetal liver cells (both genders) and wild-type adult bone marrow (both genders, mice were aged between 2.3 months old). Seed the same number of LSK into 96-well plate with 70–90% confluent OP9 cell (Gibco™ aMEM nucleosides no phenol red, Thermo Fisher Scientific, USA/20% FBS). Meanwhile, transduce MIGR1 (Vector)/PU.1-wt/Q202L-c-Jun (Fusion) into the same number of knock-in LSK using RetroNectin™ (Takara, Japan). After 72 h culture, seed all of the transduced LSK into 96-well plate with 70–90% confluent OP9 cell as well. Change medium (X-VIVO™ 15, Lonza, Switzerland/2% BSA/5 ng/ml Flt3-L/1 ng/ml IL-7, PeproTech™, USA/Penicillin/Streptomycin) every 3 days. On day 14, after the seeding of LSK, harvest cells and stain. Identify B cell by Flow Cytometry.

**Generation of PU.1 knock-in mice.** To generate mice with the point mutations in the Ets domain, the targeting strategy is outlined in Fig. 3a. We used a targeting vector carrying exons 3–5 of PU.1 in which the point mutation was introduced by site-directed mutagenesis. For the positive selection of targeted ES cells, we inserted a neomycin selection cassette driven by the PGK promoter and flanked by loxP sites between exons 3 and 5. A negative selection cassette containing HSV-thymidine kinase driven by the PGK promoter was added to the 3’ end of the targeted region. A 1.4 kb EcoRI-BamHI fragment located just 3’ of murine PU.1 exon 5 was used as a probe for Southern blot. The correct genomic insertion was tested by Southern blot analysis, and the presence of the point mutation was verified by sequencing (Fig. 3b).
**Table 2 All genes significantly dysregulated in PU.1 mutant GMP-like cells.**

| Gene symbol | Gene title                                      | Probe ID        | Fold change (log2) |
|-------------|-------------------------------------------------|-----------------|-------------------|
| Ldhb        | Lactate dehydrogenase B                         | 1434499_a_at    | −7.43             |
| Ms4a3       | Membrane-spanning 4-domains, subfamily A, member 3 | 1420572_a_at    | −6.79             |
| Ms4a6b      | Membrane-spanning 4-domains, subfamily A, member 6B | 1418826_a_at    | −6.06             |
| B4galnt6    | UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 6 | 1423228_a_at    | −5.91             |
| LOC675709   | Similar to Beta-1,4-galactosyltransferase 6 (Beta-1,4-GalTase 6) | 1463029_a_at    | −5.82             |
| Ms4a6c      | Membrane-spanning 4-domains, subfamily A, member 6 C | 1450234_a_at    | −5.64             |
| Nckap1l     | NCK associated protein 1 like                   | 1428786_a_at    | −5.09             |
| BC027057    | cDNA sequence BC027057                          | 1444546_a_at    | −5.07             |
| Cd300a      | CD300A antigen                                  | 1435903_a_at    | −4.95             |
| Tclcf       | Transcription factor EC                         | 1419537_a_at    | −4.91             |
| LOC675709   | Similar to Beta-1,4-galactosyltransferase 6 (Beta-1,4-GalTase 6) | 1435759_a_at    | −4.40             |
| Mat2c       | Myocyte enhancer factor 2 C                     | 1421027_a_at    | −4.28             |
| Hmmt        | Histamine N-methyltransferase                   | 1417702_a_at    | −3.66             |
| Sfk2a12     | Solute carrier family 25 (mitochondrial carrier, Aralar), member 12 | 1428440_a_at    | −3.19             |
| Cct9        | Chemokine (C-C motif) ligand 9                  | 1417936_a_at    | −3.06             |
| Rab31       | RAB31, member RAS oncogene family               | 1416165_a_at    | −3.00             |
| Tes         | Testis derived transcript                       | 1460378_a_at    | −2.91             |
| Cd34        | CD34 antigen                                    | 1416072_a_at    | −2.87             |
| SLC6a10     | Solute carrier family 16 (monocarboxylic acid transporters), member 10 | 1436368_a_at    | −2.67             |
| Lyz         | Lysozyme                                        | 1439426_x_at    | −2.03             |
| Igfbp4      | Insulin-like growth factor binding protein 4    | 1423756_s_at    | −1.59             |
| Ctn2        | Centrin 2                                       | 1418579_at      | −1.10             |
| Chib        | Casitas B-lineage lymphoma b                    | 1418469_at      | −1.67             |
| Rec8        | REC8 homolog (yeast)                            | 1419147_at      | −2.05             |
| LOC1000453  | Similar to Synaptotagmin-like                   | 1425787_a_at    | −2.71             |
| 07///Syt13   | 3///synaptotagmin-like                          |                 |                   |
| Sdc2        | Syndecan 2                                      | 1448545_a_at    | −2.77             |
| NA          | NA                                              | 1445627_a_at    | −3.29             |
| Trat1       | T-cell receptor associated transmembrane adaptor 1 | 1427532_a_at    | −3.83             |
| Sfk2a63     | Solute carrier family 26, member 3              | 1421445_at      | −4.11             |
| Aqp3        | Aquaporin 3                                     | 1422008_a_at    | −6.35             |

**Table 3 Unaffected PU.1 Target Genes.**

| Gene symbol | Gene title        | Probe ID        | Fold change (log2) |
|-------------|-------------------|-----------------|-------------------|
| Sfpi1       | SFFV proviral integration 1 | 1418747_at      | 0.12              |
| Jun         | Jun oncogene      | 1448694_at      | 1.01              |
| JunB        | JunB oncogene     | 1415899_at      | 0.13              |
| Blink       | B-cell linker     | 1451780_at      | 0.08              |
| CD14        | CD14 antigen      | 1417268_at      | 0.90              |
| Ly96        | Lympocyte antigen 96 | 1449874_at      | 1.08              |

**RNA isolation, amplification, and array expression analysis.** ST-HSC (lin− c-kit+ Sca-1+ CD150− CD48−) and GMP (lin− c-kit+ Sca-1− CD16/32hi CD34+) were sorted by FACS and RNA was prepared by RNeasy Micro kit (Qiagen). Ten nanograms of total RNA were used for linear amplification of cDNA using the Ovation Pico RNA Amplification System (NuGen), according to the manufacturer’s instructions. Five micrograms of cRNA were biotin-labeled using the FL-Ovation cDNA Biotin Module V2 (NuGen). Following fragmentation, the labeled cRNA of each individual sample was hybridized to Affymetrix MG430 v2 microarrays (Affymetrix) and stained according to the manufacturer’s instructions. Array data have been stored in the gene expression omnibus database (www.ncbi.nlm.nih.gov/geo; accession no.: GSE27873) according to MIAME standards. Microarray data were normalized using the RMA method with R-Bioconductor, and the differentially expressed genes were identified using the Significance Analysis for Microarrays (SAM) algorithm in TM4-MeV software with the threshold set to 0 as a median number of falsely significant genes.

**ChIP-seq analysis, peak selection, and peak annotation.** To correlate gene expression with putative PU.1 binding, we analyzed the published PU.1 chromatin immunoprecipitation-coupled deep sequencing (ChIP-seq) data from GEO (GSE21512) obtained with immature myeloid PUER cell line9. The data obtained with uninduced (t = 0 h) cells were used as a control, and the specific signals appearing after 1 h, and 6 h were combined and considered as PU.1-bound regions. We considered all ChIP regions localized within a gene or its ±50 kb flanking region as potential PU.1 target sites regulating the expression of the aforementioned gene. The identified ChIP-seq regions were divided into three groups based on the expression of the targeted gene within the PU.1 mutant populations that we performed microarray expression analysis on: unchanged, upregulated, and downregulated. The corresponding DNA sequence was retrieved, and a Position Weight Matrix (PWM—mathematical representation of a TFBS) search was performed using PSCAN.

**Crystal structure visualization.** For Fig. 1, PDB: 1PUE was downloaded and representations rendered in Pymol v2.5.0.7.

Chimeric mice were derived from embryonic stem cells that were successfully targeted by homologous recombination, and several founder lines were obtained for each construct. For the Q202L mutation, two independent founder lines were kept and analyzed. Results obtained with both lines were identical. Mouse experiments and analysis of mouse cells were performed in compliance with institutional guidelines and approved by the Beth Israel Deaconess Medical Center Institutional Care and Use Committee (protocol # 006-2008).

**Quantitative real-time PCR.** RNA isolation, DNA I treatment of FACS-sorted hematopoietic cells was carried out with the RNeasy Micro kit (Qiagen) according to the manufacturer’s instructions. After reverse transcription, the resulting cDNA was PCR-amplified using a Rotor-Gene RG 6000 (Corbett). To specifically detect wild-type and mutated PU.1, TaqMan MGB probes (Invitrogen) (wild-type: 5'-CCCTCC AGTTCTCCTG-3'; Q202L mutant: 5'-CCCTCTCCGTGTTCTG-3') were used in conjunction with the following PCR primers: 5'-GCTGCTGGTGCGGGAGCCAG-3' and 5'-CGCCAGCCGCTCTTT-3'. Primers for GAPDH (Invitrogen) were used for reference.

**Statistics and reproducibility.** Student's t-tests were performed to determine the statistical significance of the experimental results.
5. Hohaus, S. et al. PU.1 (Spi-1) and C/EBP alpha regulate expression of the SUMO1 gene under the accession number: GSE27873. The raw data from Microarray have been deposited into NCBI GEO (accession: GSE19153). The crystal structure of the PU.1 ETS domain was sourced from PDB, id 1PUE. The raw data from Microarray have been deposited into NCBI GEO (accession: GSE27873).

Supplementary Fig. S7. The crystal structure of the PU.1 ETS domain was sourced from PDB, id 1PUE. The raw data from Microarray have been deposited into NCBI GEO (accession: GSE19153). The raw data from Microarray have been deposited into NCBI GEO (accession: GSE27873).

6. Reddy, A. V. et al. Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 100, 483–490 (2002).

7. Iwasaki, H. et al. Distinctive and indispensable roles of PU.1 in maintenance of the Th2 cell response in allergen-primed mice. J. Immunol. 166, 6468–6478 (1999).

8. Akashi, K. Lineage promiscuity and plasticity in hematopoietic development. Annu. N. Y. Acad. Sci. 1044, 125–131 (2005).

9. Metcalf, D. et al. Inactivation of PU.1 in adult mice leads to the development of a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431–443 (2004).

10. Grondin, B. et al. c-Jun homodimers can function as a context-specific activator of thePU.1/2 complex. Mol. Cell. Biol. 20, 4946 (2000).

11. Akashi, K. Lineage promiscuity and plasticity in hematopoietic development. Annu. N. Y. Acad. Sci. 1044, 125–131 (2005).

12. Metcalf, D. et al. Inactivation of PU.1 in adult mice leads to the development of a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431–443 (2004).

13. Liew, C. W. Molecular analysis of the interaction between the hematopoietic master transcription factors GATA-1 and PU.1. J. Biol. Chem. 281, 28296–28306 (2006).

14. Netravali, S., Querfurth, E., Kulesza, H. & Graf, T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 95, 2543–2551 (2000).

15. Stapha, T., Amatruda, D. F., Papetti, M. & Skoulitchi, A. I. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J. 24, 3712–3721 (2005).

16. Takemoto, C. M. et al. PU.1 positively regulates GATA-1 expression in mast cells. J. Immunol. 184 4349–4361 (2010).

17. Zhang, P. et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl Acad. Sci. USA 96, 8705–8705 (1999).

18. Zhang, P. et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 96, 2641–2641 (2000).

19. Walsh, J. C. et al. Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates. Immunity 17, 665–676 (2002).

20. Chang, H. C. et al. PU.1 regulates TCR expression by modulating GATA-3 activity. J. Immunol. 183, 4887–4887 (2009).

21. Chang, H. C. et al. PU.1 expression delineates hematopoiesis in primary Th2 cells. Immunity 22, 693–703 (2005).

22. Petrovick, M. S. et al. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol. Cell. Biol. 18, 3915–3915 (1998).

23. Ueki, N., Zhang, L. & Haymann, M. J. Ski can negatively regulate macrophage differentiation through its interaction with PU.1. Oncogene 27, 300–307 (2007).

24. Laricchia-Robbio, L., Premanand, K., Rinaldi, C. R. & Nucifora, G. EVI1 impairs myelopoiesis by deregulation of PU.1 function. Cancer Res. 69, 1633–1633 (2009).

25. Rekhtman, N. et al. PU.1 and pRb interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol. Cell. Biol. 23, 7460–7460 (2003).

26. Wei, F., Zapraszka, K., Wang, J. & Atchison, M. L. PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells. Mol. Cell. Biol. 29, 4612–4620 (2009).

27. Pongubala, J. M. et al. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3’ enhancer activity. Mol. Cell. Biol. 12, 368–378 (1992).

28. Meraro, D. et al. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J. Immunol. 163, 6468–6479 (1999).

29. Akashi, K. Lineage promiscuity and plasticity in hematopoietic development. Annu. N. Y. Acad. Sci. 1044, 125–131 (2005).

30. Rekhtman, N., Radparvar, F., Evans, T. & Skoulitchi, A. I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev. 13, 1398–1411 (1999).

31. Lord, K. A., Abdolali, A., Hoffman-Liebermann, B. & Liebermann, D. A. Prote- oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol. Cell. Biol. 13, 841–851 (1993).

32. Mecha-Grigoriou, F., Gerald, D. & Yaniv, M. The mammalian Jun proteins: redundancy and specificity. Oncogene 20, 2378–2388 (2001).

33. Ischumi, W., Passegué, E. & Wagner, E. F. AP-1 in mouse development and tumourigenesis. Oncogene 20, 2401–2412 (2001).

34. Passegué, E., Wagner, E. F. & Weissman, I. L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431–443 (2004).

35. Gaynor, R., Simon, K. & Koeppler, F. Expression of c-jun during macrophage differentiation of HL-60 cells. Blood 77, 2618–2623 (1991).

36. Hass, R., Prudovsky, I. & Krugheffer, M. Differential effects of phorbol ester on signaling and gene expression in human leukemia cells. Leuk. Res. 21, 589–594 (1997).

37. Sherman, M. L., Stone, R. M., Datta, R., Bernstein, S. H. & Kufe, D. W. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J. Biol. Chem. 265, 3320–3323 (1990).

38. Grant, S. et al. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monomyelocytic leukemia cells (U937) expressing a c-jun dominant-negative mutant protein (TAM67). Cell Growth Diff. 7, 603–613 (1996).

39. Behre, G. et al. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J. Biol. Chem. 274, 4939–4946 (1999).

40. Grondin, B. et al. c-Jun homodimers can function as a context-specific coactivator. Mol. Cell. Biol. 27, 2919–2933 (2007).

41. Jia, X., Lee, L. K., Light, J., Palmer, A. G. & Assa-Munt, N. Backbone dynamics of a short PU.1 ETS domain. J. Mol. Biol. 292, 1083–1093 (1999).

42. Kodandapani, R. et al. A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex. Nature 380, 456–460 (1996).

43. Bassuk, A. G. & Leiden, J. M. A direct physical association between ETS and AP-1 transcription factors in normal human T cells. Immunity 3, 223–235 (1995).

44. Vangala, R. K. et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8; 21) myeloid leukemia. Blood 101, 270–270 (2003).

45. Uppaluri, R. & Towle, H. C. Genetic dissection of thyroid hormone receptor beta: identification of mutations that separate hormone binding and transcriptional activation. Mol. Cell. Biol. 15, 1499–1522 (1995).

46. Shih, H. M. et al. A positive genetic selection for disrupting protein-protein interactions: identification of CREB mutations that prevent association with the coactivator CBP. Proc. Natl Acad. Sci. USA 93, 13896–13901 (1996).
51. Szabo, E., Preis, L. H. & Birrer, M. J. Constitutive cJun expression induces partial macroage differentiation in U-937 cells. Cell Growth Diff. 5, 439–446 (1994).

52. Li, J., King, I. & Sartorelli, A. C. Differentiation of WEHI-3B D- myelomonocytic leukemia cells induced by ectopic expression of the protooncogene c-jun. Cell Growth Diff. 5, 743–751 (1994).

53. Wang, X. & Studzinski, G. P. The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3. Cancer Res. 66, 4402–4409 (2006).

54. Anderson, K. L., Smith, K. A., Pio, F., Torbett, B. E. & Maki, R. A. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. Blood 92, 1576–1576 (1998).

55. Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792 (1998).

56. Weigelt, K., Lichtinger, M., Rehl, M. & Langmann, T. Transcriptional profiling identifies a PU.1 regulatory network in macrophages. Biochem. Biophys. Res. Commun. 380, 308–312 (2009).

57. Otero, K. et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat. Immunol. 10, 734–743 (2009).

58. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).

59. Zambelli, F., Pesole, G. & Pavesi, G. Ps can: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res. 37, W247–W252 (2009).

60. Portales-Casamar, E. et al. JASPAR 2010: the greatly expanded open-access human transcription factor database. Nucleic Acids Res. 38, D105–D110 (2010).

61. Radis, G. et al. Diversity and complexity in DNA recognition by transcription factors. Science 324, 1720–1723 (2009).

62. Gangenahalli, G. U. et al. Stem cell fate specification: role of master regulatory switch transcription factor PU.1 in differential hematopoiesis. Stem Cells Dev. 14, 140–152 (2005).

63. Tenen, D. G., Hromas, R., Licht, J. D. & Zhang, D. E. Transcription factors, normal myeloid development, and leukemia. Blood 90, 489–519 (1997).

64. Spooner, C. J., Cheng, J. X., Pujadas, E., Laslo, P. & Singh, H. A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. Immunity 31, 576–586 (2009).

65. Steidl, U. et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat. Genet. 38, 1269–1277 (2006).

66. Adolfsson, J. et al. Identification of Flt3- lympho-myeloid stem cells lacking erythro-megakaryocytic potentialia revised road map for adult blood lineage commitment. Cell 121, 295–306 (2005).

67. Lavaux, C., Stilvassy, S. J., Slany, R. & Cleary, M. L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 16, 4226–4237 (1997).

68. Hijiguchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of t(8;21) acute myeloid leukemia. Cancer Cell 1, 63–74 (2002).

69. Hunfly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).

70. Pahl, H. L. et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J. Biol. Chem. 268, 5014–5020 (1993).

71. Behre, G., Smith, L. T. & Tenen, D. G. Use of a promoterless Rennia luciferase vector as an internal control plasmid for transient co-transfection assays of Rass-mediated transcription activation. BioTechniques 26, 24–26, 28-24-26, 28 (1999).

72. DeKoter, R. P., Lee, H.-J. & Singh, H. P. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 16, 297–309 (2002).

73. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116–5121 (2001).

74. Saeed, A. I. et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 34, 374–378 (2003).

75. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.8 (2015).

Acknowledgements
This work was funded by NIH grants 1R35CA197697 and P01HL131477, as well as the Singapore Ministry of Health’s National Medical Research Council under its Singapore Translational Research (StAR) Investigator Award to D.G.T. and the Scientific Research Training Program for Young Talents of Wuhan Union Hospital to X.Z. We thank members of the Tenen laboratory for discussions, Richard Goodman for yeast split-hybrid strains and reagents, Carol Stocking for providing PHCMV-A-MLVenv, pCaspol, and retroviral transfection protocols, Bruce Torbett for 503 cells, Harinder Singh for the MIGRI-PU.1-GFP retrovirus, and Mary Singleton and Alison Lugay for excellent assistance. B.Q.T. was funded by the National Cancer Institute Grant K01, CA222707.

Author contributions
X.Z., B.B., Y.Y., and E.K.E. performed experiments, analyzed data, and contributed to writing the manuscript. M.A.J. and P.B.S. assisted in the mouse studies. P.Z. and J.Z. maintained mouse colonies. J.D.C. and T.H. assisted in the design of this study. T.B. performed the microarray analysis and provided critical feedback. B.Q.T. contributed to preparation of the manuscript. M.A.B. analyzed data and wrote the manuscript. D.G.T. supervised the project, analyzed, and wrote the manuscript.

Competing interests
E.K.E. is a member of MOMA Therapeutics, Cambridge, MA, USA. The remaining authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03888-7.

Correspondence and requests for materials should be addressed to Mahmoud A. Bassal or Daniel G. Tenen.

Peer review information Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Christina Karlsson Rosenthal.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.